247 related articles for article (PubMed ID: 28532569)
1. Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.
Chic N; Mayo-de-Las-Casas C; Reguart N
J Thorac Oncol; 2017 Jun; 12(6):e78-e80. PubMed ID: 28532569
[No Abstract] [Full Text] [Related]
2. Successful AZD9291 Therapy in Advanced Non-Small Cell Lung Cancer after Failure of HM61713.
Chen CW; Kuo CW; Chen YL; Ho CL; Su WC; Lin CC
J Thorac Oncol; 2017 Jun; 12(6):e72-e74. PubMed ID: 28532566
[No Abstract] [Full Text] [Related]
3. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
4. Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC.
Chen K; Zhou F; Shen W; Jiang T; Wu X; Tong X; Shao YW; Qin S; Zhou C
J Thorac Oncol; 2017 Jun; 12(6):e65-e68. PubMed ID: 28093244
[No Abstract] [Full Text] [Related]
5. Osimertinib effective in EGFR T790M-positive lung cancer.
Mayor S
Lancet Oncol; 2017 Jan; 18(1):e9. PubMed ID: 27989430
[No Abstract] [Full Text] [Related]
6. Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer.
Arulananda S; Do H; Musafer A; Mitchell P; Dobrovic A; John T
J Thorac Oncol; 2017 Nov; 12(11):1728-1732. PubMed ID: 28843359
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
[TBL] [Abstract][Full Text] [Related]
8. NICE approves osimertinib for advanced lung cancer.
Burki TK
Lancet Respir Med; 2016 Dec; 4(12):954. PubMed ID: 27814987
[No Abstract] [Full Text] [Related]
9. CNS efficacy of osimertinib in EGFR-mutated advanced NSCLC.
Gourd E
Lancet Oncol; 2018 Oct; 19(10):e516. PubMed ID: 30197172
[No Abstract] [Full Text] [Related]
10. Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors.
Szymański FM; Płatek AE; Dziadziuszko R; Łęgosz P; Palczewski P
Kardiol Pol; 2018; 76(3):670. PubMed ID: 29558014
[No Abstract] [Full Text] [Related]
11. [Osimertinib (Tagrisso
Giroux Leprieur E; Cortot AB; Cadranel J; Wislez M
Bull Cancer; 2016 Oct; 103(10):815-821. PubMed ID: 27641462
[TBL] [Abstract][Full Text] [Related]
12. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
Goss G; Tsai CM; Shepherd FA; Bazhenova L; Lee JS; Chang GC; Crino L; Satouchi M; Chu Q; Hida T; Han JY; Juan O; Dunphy F; Nishio M; Kang JH; Majem M; Mann H; Cantarini M; Ghiorghiu S; Mitsudomi T
Lancet Oncol; 2016 Dec; 17(12):1643-1652. PubMed ID: 27751847
[TBL] [Abstract][Full Text] [Related]
13. Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.
Sullivan I; Planchard D
Ther Adv Respir Dis; 2016 Dec; 10(6):549-565. PubMed ID: 27784815
[TBL] [Abstract][Full Text] [Related]
14. Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer.
Carlisle JW; Ramalingam SS
Future Oncol; 2019 Mar; 15(8):805-816. PubMed ID: 30657347
[TBL] [Abstract][Full Text] [Related]
15. The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.
Remon J; Menis J; Hasan B; Peric A; De Maio E; Novello S; Reck M; Berghmans T; Wasag B; Besse B; Dziadziuszko R
Clin Lung Cancer; 2017 Sep; 18(5):583-588. PubMed ID: 28341106
[TBL] [Abstract][Full Text] [Related]
16. Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid.
Théoleyre S; Masson I; Herbreteau G; Vallée A; Sénellart H; Denis MG
Lung Cancer; 2017 Dec; 114():111-112. PubMed ID: 29096978
[No Abstract] [Full Text] [Related]
17. Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer.
Stratmann JA; Michels S; Hornetz S; Christoph DC; Sackmann S; Spengler W; Bischoff H; Schäfer M; Alt J; Müller A; Laack E; Kimmich M; Griesinger F; Sebastian M
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2457-2463. PubMed ID: 30244389
[TBL] [Abstract][Full Text] [Related]
18. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
19. Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm.
Pakkala S; Ramalingam SS
Hematol Oncol Clin North Am; 2017 Feb; 31(1):83-99. PubMed ID: 27912836
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study.
Lin CC; Shih JY; Yu CJ; Ho CC; Liao WY; Lee JH; Tsai TH; Su KY; Hsieh MS; Chang YL; Bai YY; Huang DD; Thress KS; Yang JC
Lancet Respir Med; 2018 Feb; 6(2):107-116. PubMed ID: 29249325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
